Skip to main content

Immunovant, Inc.

IMVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001764013

In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.

Members of Congress who traded IMVT

No member of Congress has reported a trade in Immunovant, Inc. since 2020.

Source: U.S. House Clerk and Senate Office of Public Records (eFD). Amounts are the ranges filers report.